Clinical trial • Phase I • Oncology
LY3410738 for IDH1/IDH2-mutant advanced solid tumours | Cholangiocarcinoma | Chondrosarcoma | Glioma
Phase I trial of LY3410738 for IDH1/IDH2-mutant advanced solid tumours | Cholangiocarcinoma | Chondrosarcoma | Glioma. 20 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- IDH1/IDH2-mutant advanced solid tumours | Cholangiocarcinoma | Chondrosarcoma | Glioma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 12-09-2024
- First CTIS Authorization Date
- 29-10-2024
Trial design
Phase I trial across 3 sites in France, Spain.
- Biomarker Stratified
- True, biomarker: IDH1 R132; IDH2 R140; IDH2 R172
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 61
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 3
France
- Earliest CTIS Part Ii Submission Date
- 23-09-2024
- Latest Decision Or Authorization Date
- 31-03-2025
- Processing Time Days
- 189
- Number Of Sites
- 2
- Number Of Participants
- 2
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Drug Development department and GI Oncology
- Principal Investigator Name
- Antoine Hollebecque
- Principal Investigator Email
- antoine.hollebecque@gustaveroussy.fr
- Contact Person Name
- Antoine Hollebecque
- Contact Person Email
- antoine.hollebecque@gustaveroussy.fr
- Site Name
- Institut Bergonie
- Department Name
- Medical Oncology
- Principal Investigator Name
- Antoine Italiano
- Principal Investigator Email
- a.italiano@bordeaux.unicancer.fr
- Contact Person Name
- Antoine Italiano
- Contact Person Email
- a.italiano@bordeaux.unicancer.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 23-09-2024
- Latest Decision Or Authorization Date
- 20-01-2026
- Processing Time Days
- 484
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Principal Investigator Name
- Jaume Capdevilla Castellon
- Principal Investigator Email
- jcapdevila@vhio.net
- Contact Person Name
- Jaume Capdevilla Castellon
- Contact Person Email
- jcapdevila@vhio.net
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY3410738
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)